Question 1

What is AbbVie stock price today?

Accepted Answer

The current price of AbbVie is 189.77 USD — it has decreased by -0.07% in the past 24 hours. Watch AbbVie stock price performance more closely on the advanced chart.

Question 2

What is AbbVie stock ticker?

Accepted Answer

Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie stocks are traded under the ticker ABBV.

Question 3

Is ABBV stock price going up?

Accepted Answer

ABBV stock has increased by 8.56% in the past week, has increased by 4.75% in the past month, and has increased by 12.51% in the past year. See more data on ABBV chart.

Question 4

What is the analyst recommendation for ABBV?

Accepted Answer

As of February 25, out of 12 analyst recommendations, the majority rate ABBV as a buy.

Question 5

What is ABBV market cap?

Accepted Answer

As of today, ABBV has the market capitalization of 336B USD. Explore our list of stocks ranked by market cap to compare ABBV with other stocks.

Question 6

Does ABBV release financial reports?

Accepted Answer

Yes, you can track ABBV financials in yearly and quarterly reports on Profit.com.

Question 7

When is ABBV next earnings date?

Accepted Answer

ABBV is going to release the next earnings report on 24 Apr 2025. Keep track of upcoming events with our Earnings Calendar.

Question 8

What were ABBV Earnings for the last quarter?

Accepted Answer

ABBV reported earnings of $3 per share for the last quarter, higher then the estimate of $2.92 per share, resulting in a 2.74% surprise. The estimated earnings for the next quarter are $2.258 per share. See more details about ABBV earnings on Profit.com.

Question 9

What was ABBV Revenue for the last quarter?

Accepted Answer

ABBV's revenue for the last quarter was 14.46B USD, lower then the estimated 14.68B USD. The estimated revenue for the next quarter is 14.86B USD See more stats in ABBV financial reports on Profit.com.

Question 10

What was ABBV Net Income for the last quarter?

Accepted Answer

ABBV net income for the last quarter is 1.56B USD, while the quarter before that showed 1.37B USD of net income which accounts for 13.94% change. See more stats in ABBV financial reports on Profit.com.

Question 11

Does ABBV pay dividends?

Accepted Answer

No, ABBV doesn't pay any dividends to its shareholders. But you can explore a list of high-dividend stocks on Profit.com.

Question 12

How many employees does ABBV have?

Accepted Answer

As of 05 Feb 2025, ABBV employs approximately 50000 employees. Check out if ABBV is on our list of largest employers.

Question 13

What is ABBV EBITDA?

Accepted Answer

EBITDA, which measures a company's operating performance, reflects its efficiency improvements. ABBV EBITDA is 25.63B USD, with a current EBITDA margin of 9.22%. See more stats in ABBV financial reports on Profit.com.

Question 14

How to buy ABBV stocks?

Accepted Answer

Like other stocks, ABBV shares are traded on stock exchanges such as NYSE. The easiest way to buy them is through an online stock broker. Simply open an account, follow the broker's procedures, and start trading. Alternatively, you can practice trading Tesla stock on Profit.com in Playtrade Tournaments or choose a recommended broker to trade directly.

Question 15

Should I invest in ABBV stock?

Accepted Answer

Investing in stocks requires thorough research, including analyzing the company’s financials, related news, and technical analysis. Currently, Tesla's technical analyst recommendations show a buy rating.

Before investing in ABBV, consider subscribing to Profit PRO where can practice trading in Playtrade Tournaments, access AI-powered daily market insights, copy expertly handpicked Watchlists, and follow Billionaire Portfolios.

AbbVie Inc

AbbVie closes $200M Nimble Therapeutics acquisition

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more

AbbVie to buy Aliada Therapeutics for $1.4B in cash

AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

AbbVie cuts 2024 profit forecast citing R&amp;D expenses https://t.co/dRM9npoJjV https://t.co/QNrN3lsX7b

AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets https://t.co/s5PM7sArdj https://t.co/fmmnx6uJlG

AbbVie completes acquisition of Cerevel Therapeutics

Cerevel Therapeutics ticks higher amid Nasdaq delisting notice for AbbVie deal

Cerevel gains as AbbVie says it expects deal to close soon (update)

Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie

AbbVie cuts 2024 profit forecast on R&amp;D expenses https://t.co/WTkmzTGw1V https://t.co/EOEaZXsEJq

Cerevel Therapeutics drops amid report on FTC review of AbbVie deal

AbbVie buys bowel disease drug developer Celsius for $250M

Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal

AbbVie says FDA approves Skyrizi for ulcerative colitis

Cerevel Therapeutics gains after AbbVie says making good progress with FTC

Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors

Landos shares rocket 170% on AbbVie takeover deal

FDA grants full approval to AbbVie/ImmunoGen drug Elahere

AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals

AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira

Cerevel, AbbVie get FTC Second Requests for more merger info

AbbVie revises Q1 earnings outlook as ImmunoGen deal closes

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

ImmunoGen spikes as HSR waiting period for AbbVie deal expires

AbbVie – Cerevel deal reportedly followed unusual options trading

AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say https://t.co/eJNLf96jCm https://t.co/CVmzjEAVVM

AbbVie – Cerevel M&A deal lifts Reviva, Karuna

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion - CNBC

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

Cerevel Therapeutics jumps after Abbvie agrees to $8.7B takeover (update)

$ABBV $CERE | AbbVie Nears Roughly $8B For Drug Developer Cerevel -Reuters https://t.co/xdE6a1KvVM

ImmunoGen downgraded on Wall Street expecting AbbVie deal success

AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash

AbbVie results beat expectations despite low-cost competition to blockbuster Humira

AbbVie buys Parkinson's disease drug developer Mitokinin

Boehringer launches 81% discounted biosimilar of AbbVie's Humira https://t.co/uBrjN0CCNX https://t.co/hbE2c2M3PH

AbbVie terminates deal with I-Mab to develop cancer drug https://t.co/YplNkesCyE https://t.co/F5u4AVZmhQ

AbbVie shares jump as results beat expectations despite blockbuster Humira’s declining sales

Earnings Outlook: AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition

Major Earnings Releases W/C July 24th $GOOGL $UBSG $T $VZ $MSFT $V $BA $KO $UNP $META $TMO $F $INTC $MCD $AMZN $MA $ABBV $SHEL $GM $XOM $AZN $CVX $PG $SNY https://t.co/7iSK0DiLXc

U.S. FDA approves Genmab-AbbVie's blood cancer therapy https://t.co/DITbQVqnrY https://t.co/Nfqfkm3VLT

U.S. FDA approves Genmab-AbbVie's blood cancer therapy https://t.co/exsqPsVQ7a https://t.co/JMAEuLwsUw

US FDA approves Genmab-AbbVie's blood cancer therapy https://t.co/txvzEO8jfv https://t.co/0g9svDtog0

Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report

AbbVie posts weak sales of newer drugs as Humira faces fresh competition, shares fall https://t.co/ZtehWs9zEp https://t.co/VhCR15G9SZ

AbbVie on track for biggest decline in about three years as newer drug sales lag estimates

FAQs

AbbVie cuts 2024 profit forecast citing R&D expenses https://t.co/dRM9npoJjV https://t.co/QNrN3lsX7b

AbbVie cuts 2024 profit forecast on R&D expenses https://t.co/WTkmzTGw1V https://t.co/EOEaZXsEJq